Novel Healthcare and Therapeutic Innovations

Rapid and fundamental innovation—ranging from digital technology to generative artificial intelligence to new methodologies in clinical research—has ushered in a plethora of new solutions and approaches that rapidly capture diagnostic, therapeutic, and patient-generated biomedical information. In many cases, existing regulatory and reimbursement frameworks have not kept pace with such changes.

Tapestry helps stakeholders collaboratively address the adoption of new technologies and approaches that could revolutionize research and development, health services delivery, access, and reimbursement.

Relevant efforts include:

• Patient-Reported Outcomes (PROs) in Early-Phase Oncology Trials: PROs are increasingly easier to collect via e-PRO solutions but historically have not been integrated on a large-scale basis into early-phase oncology trials to assess tolerability and inform dosing decisions. In this exploratory effort in 2025, Tapestry interviewed thought leaders to assess the promise and challenges of using PROs to advance dose optimization in the earliest phases of cancer drug development

• Digital Health and Diagnostic AI Technologies: In 2023, Tapestry partnered with the Peterson Center on Healthcare and the Gordon and Betty Moore Foundation to address the lack of resources and standards for assessing value, performance, and quality of digital health technologies and AI-enabled diagnostic decision support tools.

• Multicancer Early Detection (MCED) Initiative: MCED technologies, which aim to identify early signals of cancer, are poised to usher in a new era in cancer screening and prevention, but their introduction into the market faces complexities. Tapestry engaged diverse stakeholders to tackle concerns around MCED adoption. This work laid the foundation for a new independent organization—the MCED Consortium—to address these issues on a long-term basis.